<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150162</url>
  </required_header>
  <id_info>
    <org_study_id>037-POA-0901i</org_study_id>
    <nct_id>NCT01150162</nct_id>
  </id_info>
  <brief_title>Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation</brief_title>
  <acronym>MGES</acronym>
  <official_title>A Prospective Randomized, Multi-center Study to Assess the Safety and Efficacy of Mucosta (Rebamipide), in Combination With Omeprazole as Adjuvant Therapy in Gastric Ulcer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pakistan Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pakistan Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta
      (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing rates for gastric ulcer patients via endoscopic examination</measure>
    <time_frame>8 weeks treatment plus 4 weeks follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement or absence of gastric ulcer associated symptoms</measure>
    <time_frame>8 weeks treatment plus 4 weeks follow-up</time_frame>
    <description>Improvement or absence of gastric ulcer associated symptoms, i.e. pain, burning, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine and compare the Safety profile in both the treatment arms.</measure>
    <time_frame>8 weeks treatment plus 4 weeks follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Gastric Ulcer</condition>
  <arm_group>
    <arm_group_label>Mucosta and Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeperazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide and Omeprazole</intervention_name>
    <description>open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks</description>
    <arm_group_label>Mucosta and Omeprazole</arm_group_label>
    <other_name>Mucosta</other_name>
    <other_name>Omeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks</description>
    <arm_group_label>Omeperazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with dyspepsia or epigastric pain and endoscopically proven gastric and
             duodenal ulcers

          -  Required laboratory parameters and time limits (screening blood tests will be taken
             including hemoglobin, white blood cell count, random glucose, potassium, sodium,
             chlorine, creatinine, AST, ALT, bilirubin, and alkaline phosphatase)

          -  Age &gt; 18 years

          -  A statement that all patients must have signed an informed consent form prior to
             registration in study

        Exclusion Criteria:

          -  Patients who had undergone surgery for ulcers

          -  History of hypersensitivity to drugs to be used in the study

          -  Women who are pregnant or lactating or intended to get pregnant during the study
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Laeeque Ahmed, Asst. Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Ziauddin University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbasi Shaheed Hospital</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dow University of Health Sciences</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ziauddin University Hospital</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

